Search the Newsreel

Why Gilead Sciences (GILD) Is Back In The Spotlight

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Gilead Sciences (GILD) is back in focus after announcing a collaboration with Nucleai that applies AI powered tissue analytics to its antibody drug conjugate …

Gilead Sciences (GILD) Expands ADC Research With AI Tissue Analytics

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Gilead Sciences (NasdaqGS:GILD) announced a partnership with Nucleai to use AI-powered tissue analytics in its global antibody drug conjugate programs. The collaboration focuses …

GILD- An Attractive Biotech Stock with Solid Base Revenue Growth

Gilead Sciences Inc. (GILD) just reported June quarter revenue up 10.2% from last year to $7.8 billion, ahead of estimates. Due to an $11.2 billion one-time write-off of acquired in-process R&D, they reported a $6.75 per share pro forma loss. But that was smaller …

Notícias das Ações da Gilead Sciences Inc (GILD)

GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength

Gilead Sciences, Inc. GILD used its second-quarter 2026 call to emphasize stronger base-business growth, led by HIV, PrEP, Trodelvy and Livdelzi, while outlining a busy second-half launch calendar. Non-GAAP loss per share was $6.75, better than the Zacks Consensus Estimate for a loss of …

KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments

Kymera Therapeutics, Inc. KYMR reported a second-quarter 2026 loss of 62 cents per share, narrower than the Zacks Consensus Estimate of a loss of 64 cents. The company posted a loss of 95 cents in the year-ago period. Revenues surged to $65 million from …

Gilead Slumps As Long-Term Uncertainty Clouds Massive HIV Beat

Gilead Sciences narrowly beat sales expectations for its HIV PrEP drug, Yeztugo. Gilead stock slipped, still in a downtrend. Continue Reading

Gilead (GILD) Faces HIV Drug Access Criticism From AIDS Healthcare Foundation

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AIDS Healthcare Foundation publicly criticizes Gilead Sciences on its global HIV drug pricing and access policies. The advocacy group alleges that Gilead benefits from taxpayer-funded research while …

The Bull Case For Gilead Sciences (GILD) Could Change Following Deeper 2026 Losses Amid HIV, Oncology Growth

In early August 2026, Gilead Sciences reported second-quarter revenue of US$7.80 billion but moved to a quarterly net loss of US$10.50 billion, widened its full-year 2026 loss guidance, and still affirmed a US$0.82 per-share dividend while continuing selective share repurchases. Despite the reported loss …

Gilead Sciences in charts: Q2 base sales jump 10% on HIV, oncology growth despite Veklury drop

[ ] Seeking Alpha [ ] Seeking Alpha [ ] Seeking Alpha [ ] Seeking Alpha [ ] Seeking Alpha MORE ON GILEAD SCIENCES * Gilead Sciences, Inc. (GILD) Q2 2026 Earnings Call Transcript [https://seekingalpha.com/article/4930335-gilead-sciences-inc-gild-q2-2026-earnings-call-transcript] * Gilead Sciences, Inc. 2026 Q2 - Results - …

CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results

Product Sales Excluding Veklury Increased 10% Year-Over-Year to $7.6 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.8 billion Diluted Loss Per Share was $(8.45) and Non-GAAP Diluted Loss Per Share was $(6.75) Reflecting $(9.08) Per Share Acquired IPR&D and Tax Expenses Associated with Recent …

Gilead outlines 2026 base business sales of $29.8B-$30.1B while raising HIV growth outlook to 9%-10%

Earnings Call Insights: Gilead Sciences (GILD) Q2 2026 MANAGEMENT VIEW * "Gilead has delivered another quarter of commercial excellence with base business sales up 10% year-over-year... driven by our HIV portfolio, Trodelvy and Livdelzi," said (Chairman & CEO Daniel O'Day), adding that "we are …

Gilead Sciences Q2 Earnings Call Highlights

Key Points Interested in Gilead Sciences, Inc.? Here are five stocks we like better. Base business sales rose 10% year over year to $7.6 billion, led by HIV, oncology and liver treatments. Gilead raised its full-year base business sales outlook to $29.8 billion–$30.1 billion …

Compared to Estimates, Gilead (GILD) Q2 Earnings: A Look at Key Metrics

For the quarter ended June 2026, Gilead Sciences (GILD) reported revenue of $7.8 billion, up 10.2% over the same period last year. EPS came in at -$6.75, compared to $2.01 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of …

Gilead's High-Profile HIV Drug Beat, But That's Not What Grabbed Attention

Gilead Sciences narrowly beat sales expectations for its HIV PrEP drug, Yeztugo. Gilead stock edged lower late, still in a downtrend. Continue Reading

Gilead Sciences (GILD) Reports Q2 Loss, Beats Revenue Estimates

Gilead Sciences (GILD) came out with a quarterly loss of $6.75 per share versus the Zacks Consensus Estimate of a loss of $7.07. This compares to earnings of $2.01 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report …

AHF Crowns Gilead Corporate Welfare King

LOS ANGELES, August 04, 2026--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) condemns Gilead Sciences' greed as the drug company giant gloats over its latest quarterly financial results. The only thing new is the numbers detailing the parasitic profits from one of the worst epidemics to hit …

Gilead Sciences (NASDAQ:GILD) Beats Expectations in Strong Q2 CY2026

Gilead Sciences (NASDAQ:GILD) Beats Expectations in Strong Q2 CY2026 Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q2 CY2026 results topping the market's revenue expectations , with sales up 10.2% year on year to $7.80 billion. On the other hand, the company's full-year revenue guidance of …

Gilead second-quarter sales rise 8%, beating Wall Street estimates

By Deena Beasley Aug 4 (Reuters) - Gilead Sciences on Tuesday reported second-quarter product sales rose 8%, led by double-digit gains for its HIV drugs, but it posted a quarterly loss ‌due to costs related to a series of acquisitions. The company's overall revenue …

Could Gilead Sciences (GILD) Have a Major HIV Growth Engine in Yeztugo?

Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 …

Gilead Sciences (GILD) Q2 Earnings Report Preview: What To Look For

Gilead Sciences (GILD) Q2 Earnings Report Preview: What To Look For Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting earnings this Tuesday after market hours. Here's what to expect. Gilead Sciences beat analysts' revenue expectations last quarter, reporting revenues of $6.96 billion, up 4.4% …

Seeking Clues to Gilead (GILD) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics

The upcoming report from Gilead Sciences (GILD) is expected to reveal quarterly loss of -$7.07 per share, indicating a decline of 451.7% compared to the year-ago period. Analysts forecast revenues of $7.37 billion, representing an increase of 4% year over year. The consensus EPS …

Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Shares of this HIV and hepatitis C drugmaker have …

Gilead (GILD) Stock Stays Cheap On Its 130% Five Year Run

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Gilead Sciences stock has delivered a strong 130.1% return over the past 5 years, which raises a clear question for investors about how much …

Gilead Sciences (GILD) Following Trodelvy Progress And A Fair Value Debate

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Gilead Sciences (GILD) is back in focus after regulators in Europe issued a positive opinion on expanding Trodelvy's use alongside Keytruda for certain …

Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Atea Pharmaceuticals Inc. announced on Tuesday positive topline findings from its pivotal North American Phase 3 C-BEYOND clinical trial evaluating its oral antiviral therapy for chronic hepatitis …

Gilead Sciences (GILD) Laps the Stock Market: Here's Why

Gilead Sciences (GILD) closed the most recent trading day at $134.32, moving +2.91% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.21%. Meanwhile, the Dow gained 1.03%, and the Nasdaq, a tech-heavy index, lost 0.22%. The HIV and …

Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for

Wall Street expects a year-over-year decline in earnings on higher revenues when Gilead Sciences (GILD) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term …

FBT and IBB Are Not the Same Biotech Bet, and 5 Years of Returns Prove It

Quick Read FBT's equal-weight design beat IBB by 35 percentage points over five years, returning 47% versus IBB's 13% despite carrying a higher expense ratio. IBB puts nearly 30% into four mega-caps (Vertex, Amgen, Gilead, and Regeneron), making it behave more like a defensive …

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $129.31, moving -1.18% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 0.05% for the day. Elsewhere, the Dow gained 0.46%, while the tech-heavy Nasdaq …

CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer

– A Second Approval in First-Line Would Establish Trodelvy as a Backbone Therapy Across PD-L1 Status in the European Union – – ASCENT-04/KEYNOTE-D19 Demonstrated a Highly Statistically Significant and Clinically Meaningful Reduction in the Risk of Disease Progression or Death – FOSTER CITY, Calif., …

Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

FOSTER CITY, Calif., July 21, 2026--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2026 financial results and guidance will be released on Tuesday, August 4, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will …

Nasdaq 100 Movers: TRI, SNDK

In early trading on Tuesday, shares of SanDisk topped the list of the day's best performing components of the Nasdaq 100 index, trading up 9.7%. Year to date, SanDisk registers a 542.7% gain. And the worst performing Nasdaq 100 component thus far on the …